Bio­Marin ex­ecs dis­cuss some eye-pop­ping num­bers for the price of val­rox — but haven't we heard this be­fore?

Robert Baf­fi Bio­Marin

SAN FRAN­CIS­CO — Bio­Marin got some con­sid­er­able at­ten­tion from the Wall Street Jour­nal to­day with its rev­e­la­tion that CEO JJ Bi­en­aimé has been think­ing about charg­ing $2 mil­lion to $3 mil­lion for the com­pa­ny’s new gene ther­a­py for he­mo­phil­ia A, val­rox, which is the lead drug in the race for a pi­o­neer­ing FDA ap­proval.

It’s an im­por­tant dis­cus­sion, and we’re glad to see it play out in the gray la­dy of Street speak, which has a big reach. But close ob­servers will note that this isn’t a new num­ber. Bi­en­aime and his ex­ec­u­tive team dis­cussed that very same range back in Feb­ru­ary dur­ing their Q4 call, which we re­port­ed on. Maybe oth­ers buzzed about it as well.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER